Astria Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Astria Therapeutics, Inc.

Astria Therapeutics, Inc. is a U.S.-listed biopharmaceutical company traded on the NASDAQ in the United States (United States), focused on allergic and immunologic diseases. For French-speaking investors evaluating the name, Astria should be viewed primarily as a clinical-stage biotech, with valuation driven more by pipeline execution, regulatory milestones, and strategic transactions than by recurring commercial revenues. The company was incorporated in Delaware on June 26, 2008. Its operational base has been associated with Boston, Massachusetts, placing it in one of the most important U.S. biotech hubs. Over time, Astria has built a portfolio centered on hereditary angioedema (HAE), a rare and chronic condition, and has used that program as the anchor for its broader immunology strategy. Astria’s lead asset is navenibart, a long-acting monoclonal antibody inhibitor of plasma kallikrein designed for the preventive treatment of HAE. Recent company disclosures highlighted positive clinical data across its ALPHA-STAR and ALPHA-SOLAR development program, alongside the launch of Phase 3 studies such as ALPHA-ORBIT and ORBIT-EXPANSE. The investment case has increasingly centered on navenibart’s potential differentiation, especially around efficacy, safety, and a less frequent dosing profile that could support patient convenience and commercial adoption. The company has also pursued geographic expansion through a licensing agreement with Kaken Pharmaceutical for the development and commercialization of navenibart in Japan. This is noteworthy because it indicates Astria is not only advancing a lead asset clinically, but also selectively building regional partnerships that may help monetize the program beyond the core U.S. market. In parallel, Astria is advancing STAR-0310, an OX40 antagonist being developed for atopic dermatitis. This second program broadens the pipeline beyond HAE and shows management’s intent to create optionality in immunology. That said, Astria remains highly dependent on successful clinical execution in a competitive field where larger pharmaceutical groups and specialty biotechs are also targeting HAE and related immune-mediated diseases. Recent corporate developments are especially important. Astria reported positive clinical updates on navenibart, initiated Phase 3 work, and secured the Japan license deal. Most significantly, BioCryst Pharmaceuticals announced an acquisition of Astria, and Astria stockholders approved the transaction in January 2026. For investors, that means Astria is best understood as a NASDAQ-listed U.S. biotech whose near-term narrative has been shaped by clinical progress and a major M&A process, rather than by a mature commercial product base.